IBIO Stock Price - iBio Inc.ready to rise after shedding a quarter of its value


  • NYSEAMERICAN:IBIO gains around 2% at the beginning of August.
  • Investors remain hopeful that the micro-cap company can provide a COVID-19 vaccine.
  • Shares are set to react to updated coronavirus cases and government support. 

NYSEAMERICAN:IBIO has kicked the month off on the right foot, rising 1.80% on Monday to close at $4.52. After briefly touching a daily high of $4.68, the stock steadily fell throughout the afternoon. A lower than normal trading – volume could be a sign that investors are hesitant about buying or selling the stock ahead of its quarterly earnings announcement in mid-August. iBio Inc. also has a tremendously high short-volume-ratio at 36%, which shows that over a third of investors are banking on the stock price to fall in the future. 

Update 8: IBIO is down but not out – trading 8.5% higher in Wednesday's pre-market trading and licking its wounds from the crash of 25.2% on Tuesday. The pharma firm's issues and Russia's vaccine announcement fueled a ferocious bear attack. Robinhood traders may now jump in, especially as gold is tumbling down.

Update 7: After edging up at the beginning of Friday's session, Ibio Inc is trading some 4.68% down, changing hands under $4. IBio's links to China – working with a factory based in Beijing – may have an adverse impact. Sino-American relations are worsening. See Reports US to sanction Hong Kong leader Carrie Lam

Update 6: Friday's pre-market trading is pointing to a rebound of sorts for Ibio, with a minor rise. The company seems able to weather the storm – and especially fierce competition. Another firm, Vaxart, has been receiving attention after publishing robust financial results. Fending off competitors may not be necessary if government funding is secured.  

Update 5: Thursday's session has been characterized by selling of various shares in the electric vehicle and also coronavirus sectors. Ibio Inc. is trading around $4.20 at the time of writing, down some 4.5% and contrary to pre-market trading. Is this correction a buying opportunity? Or perhaps markets may find other stocks. Another such company is NVAX, which has three reasons to rise.

Update 4: Thursday's could turn into IBIO's day, with a projected upside open at 4.5% higher. OWS funds going to Johnson and Johnson and Dr. Anthony Fauci's drive toward immunization have both been helping all companies developing vaccines to move higher.

Update 3: Ibio Inc. has defied selling pressure and is rising around 1% in Wednesday's trading, despite opening on lower ground. It seems that the Novavax's highly publicized progress in developing immunization is lifting all companies involved in the race to provide humanity with a silver bullet – despite downbeat projections by the World Health Organization. NYSEAMERICAN: IBIO is holding its ground at $4.43 at the time of writing. 

Update 2: NYSEAMERICAN: IBIO is expected to kick off Wednesday's trading on the back foot, extending the 2.88% loss experienced on Tuesday. While Ibio's plant-based immunization sounds promising, it is essential to note that the coronavirus vaccine field is becoming crowded.

Update: Ibio Inc has kicked off Tuesday's trade some profit-taking, falling at the open but bouncing back to around $4.50 later on. Coronavirus cases in Florida, Texas, California, and other states are in play, and so is news about the next fiscal relief package. 

iBio Inc. is positioning itself well, whether it is able to create a COVID-19 vaccine, or, perhaps more realistically, it ends up helping to manufacture another company’s vaccine. Its FastPharming Facility has shown that it can mass-produce plant-based vaccines in a short period, making it an ideal partner for a successful vaccine maker. One other note that is not often mentioned is that iBio Inc. has a partnership with a vaccine company in China called CC Pharming. The significance here is that CC Pharming has already successfully created a vaccine for a sister-strain of COVID-19 – so iBio Inc. should have access to some extremely valuable information and knowledge. 

iBio Stock Forecast

 

iBio Inc. stock price may remain flat until any sort of news or announcement acts as a catalyst ahead of their earnings call. With President Donald Trump announcing that he has a desire for schools to be open come September, the next month could be a mad scramble for companies, like iBio Inc., to get a vaccine to market, if possible.

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

AUD/USD: A tough barrier remains around 0.6800

AUD/USD: A tough barrier remains around 0.6800

AUD/USD failed to maintain the earlier surpass of the 0.6800 barrier, eventually succumbing to the late rebound in the Greenback following the Fed’s decision to lower its interest rates by 50 bps.

AUD/USD News
EUR/USD still targets the 2024 peaks around 1.1200

EUR/USD still targets the 2024 peaks around 1.1200

EUR/USD added to Tuesday’s losses after the post-FOMC rebound in the US Dollar prompted the pair to give away earlier gains to three-week highs in the 1.1185-1.1190 band.

EUR/USD News
Gold surrenders gains and drops to weekly lows near $2,550

Gold surrenders gains and drops to weekly lows near $2,550

Gold prices reverses the initial uptick to record highs around the $$2,600 per ounce troy, coming under renewed downside pressure and revisiting the $2,550 zone amidst the late recovery in the US Dollar.

Gold News
Australian Unemployment Rate expected to hold steady at 4.2% in August

Australian Unemployment Rate expected to hold steady at 4.2% in August

The Australian Bureau of Statistics will release the monthly employment report at 1:30 GMT on Thursday. The country is expected to have added 25K new positions in August, while the Unemployment Rate is foreseen to remain steady at 4.2%.

Read more
Ethereum could rally to $2,817 following Fed's 50 bps rate cut

Ethereum could rally to $2,817 following Fed's 50 bps rate cut

Ethereum (ETH) is trading above $2,330 on Wednesday as the market is recovering following the Federal Reserve's (Fed) decision to cut interest rates by 50 basis points. Meanwhile, Ethereum exchange-traded funds (ETF) recorded $15.1 million in outflows.

Read more
Moneta Markets review 2024: All you need to know

Moneta Markets review 2024: All you need to know

VERIFIED In this review, the FXStreet team provides an independent and thorough analysis based on direct testing and real experiences with Moneta Markets – an excellent broker for novice to intermediate forex traders who want to broaden their knowledge base.

Read More

Forex MAJORS

Cryptocurrencies

Signatures